The clinical significance of serum VEGF C, VEGF D and sVEGFR2 concentration in lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
Clinical significance of serum osteopontin levels in lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
The levels of osteoprotegerin (OPG), interleukin 18 (IL-18) and soluble interleukin 2 receptor (sIL-2R) in serum during chemotherapy of lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 318s Year: 2004
Prognostic significance of three tumor markers (CA125, CEA, and TPA) in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Clinical significance of serum survivin, MGB-1 and Pref-1 levels during chemotherapy of lung cancer Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
The clinical significance of serum interleukin 18 concentration in lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 394s Year: 2003
Clinical significance of serum adipokines levels in lung cancer Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Prognostic significance of plasma D-dimer (DD) in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002
Prognostic and predictive value of cytokeratin-19 fragments (Cyfra 21-1), carcinoembryonic antigen (CEA) and human chorionic gonadotropin (bHCG) in 138 NSCLC patients - 5 years of observation Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Usefulness of serum procalcitonin in lung cancer patients with elevated serum C-reactive protein level Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
A serum level of IGF-I, IGF-II and IGFBP-3 in patients with small cell lung cancer (SCLC) during chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 86s Year: 2006
Serum levels of thrombopoietin (TPO) in patients with thrombocytosis due to lung cancer and in essential throbocythaemia (ET) Source: Eur Respir J 2001; 18: Suppl. 33, 234s Year: 2001
Importance of tumour markers CYFRA 21-1 and NSE serum concentration values in diagnosis and esteem of nonmicrocelullar lung cancer expansion Source: Eur Respir J 2005; 26: Suppl. 49, 325s Year: 2005
Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Serum levels of sFas and sFasL during chemotherapy of lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 329s Year: 2005
Clinical value of soluble interleukine-2 receptor (sIL-2R) serum level examination in the pulmonary sarcoidosis (PS) Source: Eur Respir J 2003; 22: Suppl. 45, 226s Year: 2003
A serum level of IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 329s Year: 2005
Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003
IGF-I and IGFBP-3 concentrations in the blood serum and lung cancer risk Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011